PDCD1 and metastatic melanoma: Although antibodies against CTLA4 and PD-1, used alone or in combination, both can exert a certain curative effect on the unresectable or metastatic melanoma, the clinical benefits remain unsatisfactory owing to the relatively low ORRs and the phenomenon of drug-resistance (65).